27,491 Shares in Xencor, Inc. (NASDAQ:XNCR) Acquired by Wellington Management Group LLP

Wellington Management Group LLP bought a new position in Xencor, Inc. (NASDAQ:XNCR - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 27,491 shares of the biopharmaceutical company's stock, valued at approximately $632,000.

Several other institutional investors also recently bought and sold shares of the business. Sterling Capital Management LLC increased its stake in shares of Xencor by 732.4% during the 4th quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 1,040 shares during the last quarter. GF Fund Management CO. LTD. purchased a new stake in Xencor in the fourth quarter valued at approximately $34,000. KBC Group NV increased its position in Xencor by 26.0% during the fourth quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company's stock worth $90,000 after purchasing an additional 813 shares during the last quarter. PNC Financial Services Group Inc. raised its stake in Xencor by 49.4% during the fourth quarter. PNC Financial Services Group Inc. now owns 4,041 shares of the biopharmaceutical company's stock worth $93,000 after purchasing an additional 1,337 shares during the period. Finally, Mackenzie Financial Corp purchased a new position in Xencor during the fourth quarter worth approximately $101,000.

Xencor Price Performance

Shares of NASDAQ XNCR opened at $9.65 on Friday. Xencor, Inc. has a 1-year low of $7.16 and a 1-year high of $27.24. The business has a 50-day moving average of $8.98 and a 200-day moving average of $15.66. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23. The company has a market capitalization of $686.80 million, a price-to-earnings ratio of -3.02 and a beta of 0.87.

Xencor (NASDAQ:XNCR - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.06). Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The company had revenue of $32.73 million for the quarter, compared to analyst estimates of $23.44 million. During the same period last year, the firm posted ($1.11) earnings per share. The business's revenue was up 104.6% on a year-over-year basis. On average, equities analysts anticipate that Xencor, Inc. will post -3.68 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently commented on XNCR. Barclays dropped their price objective on Xencor from $22.00 to $6.00 and set an "underweight" rating for the company in a report on Thursday, May 8th. Wall Street Zen downgraded Xencor from a "hold" rating to a "sell" rating in a research report on Friday, March 14th. Wedbush restated an "outperform" rating and issued a $31.00 price objective on shares of Xencor in a report on Wednesday, April 30th. William Blair started coverage on Xencor in a research note on Monday, April 21st. They issued an "outperform" rating on the stock. Finally, Wells Fargo & Company dropped their target price on shares of Xencor from $37.00 to $33.00 and set an "overweight" rating for the company in a research report on Friday, February 28th. Two analysts have rated the stock with a sell rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $29.50.

Insider Transactions at Xencor

In related news, EVP Nancy Valente sold 4,616 shares of the firm's stock in a transaction on Friday, May 2nd. The shares were sold at an average price of $11.03, for a total transaction of $50,914.48. Following the completion of the sale, the executive vice president now directly owns 49,169 shares of the company's stock, valued at approximately $542,334.07. This trade represents a 8.58% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 4.76% of the company's stock.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.